Today, India's Supreme Court rejected an application from Novartis AG for a patent on a cancer drug. This is a landmark ruling that will ensure that poor patients worldwide will have access to lifesaving medications.
Novartis' application asked for a new patent to protect its investment in the cancer drug Glivec. India has a large generic drug industry - almost $26 billion - so this decision impacts much of the developing world.
AMSA continues to pressure pharmaceutical companies to provide affordable medicines to developing countries and lobbies to ensure that international trade regulations afford the right to do so.
Read more from the New York Times.